Mfsd2a overexpression alleviates vascular dysfunction in diabetic retinopathy

Area of Science:

• Ophthalmology
• Biochemistry
• Molecular Biology

Background:

• Diabetic retinopathy (DR) is a common complication of diabetes, with current treatments like ranibizumab showing limited success in some patients.
• Docosahexaenoic acid (DHA), an omega-3 fatty acid, is known to reduce abnormal neovascularization in eye diseases.
• However, the therapeutic effectiveness of DHA for conditions like diabetic macular edema (DME) is inconsistent, prompting investigation into underlying mechanisms.

Purpose of the Study:

• To investigate the reasons behind the variable effectiveness of DHA therapy in patients with diabetic retinopathy.
• To explore the role of Mfsd2a, a transporter for DHA, in the context of DR and its potential impact on treatment outcomes.

Main Methods:

• Analysis of fatty acid composition in vitreous humor samples from DR and macular hole patients.
• Assessment of Mfsd2a expression in animal models of retinopathy (oxygen-induced retinopathy and streptozotocin-induced diabetes).
• In vitro studies using endothelial cells to evaluate the functional impact of Mfsd2a overexpression and DHA treatment.

Main Results:

• Vitreous humor from DR patients showed altered ratios of DHA and its metabolites compared to controls, with a lower proportion of metabolites relative to DHA.
• Mfsd2a expression was found to be reduced in animal models of retinopathy.
• In vitro, Mfsd2a overexpression inhibited endothelial cell functions, and its combination with DHA diet significantly reduced neovascularization and vascular leakage in OIR models.

Conclusions:

• Low expression of the Mfsd2a transporter is a key factor contributing to the failure of DHA therapy in some diabetic retinopathy patients.
• Overexpression of Mfsd2a combined with DHA administration presents a potential therapeutic strategy to improve treatment efficacy for diabetic retinopathy.